Mu-Opioid Receptors in the Amygdala Control Feeding Behavior
Only mu-opioid activation in the amygdala increased food intake — delta and kappa agonists had no effect — showing appetite control is receptor-specific in this brain region.
Quick Facts
What This Study Found
The mu-selective opioid agonist DAGO (Tyr-D-Ala-Gly-(Me)Phe-Gly-ol) increased food intake when injected into the central nucleus of the amygdala at doses of 1 and 3 nanomoles.
Neither DSLET (a delta-selective agonist) nor dynorphin A (a kappa-selective agonist) affected food intake at the same location, even at the highest dose of 3 nanomoles.
Dynorphin A did increase food intake when injected into the medial hypothalamus at 2 nanomoles. This shows that different brain regions use different opioid receptor types to control eating.
Bilateral injections of DAGO were no more effective than unilateral injections. Naloxone and the long-acting antagonist beta-chlornaltrexamine both blocked DAGO's feeding effect, confirming opioid receptor involvement.
Key Numbers
How They Did This
Rats received unilateral or bilateral microinjections of receptor-selective opioid agonists into the central nucleus of the amygdala or medial hypothalamus. Food intake was measured. Antagonists (naloxone, beta-chlornaltrexamine) tested specificity. All tested in rats, not people.
Why This Research Matters
The amygdala processes emotions and reward. Finding that mu-opioid receptors there control feeding connects the emotional/reward aspects of eating with the opioid system. This is relevant to understanding binge eating, emotional eating, and food addiction.
The Bigger Picture
Understanding which opioid receptors in which brain regions control appetite could lead to targeted treatments for obesity and eating disorders without the side effects of broad opioid manipulation.
What This Study Doesn't Tell Us
Tested in rats, not people. Direct brain injection is not clinically relevant. Only three receptor types tested. The relationship between opioid-driven feeding in rats and human eating behavior is uncertain. Did not test whether this pathway is involved in normal eating or only pharmacological overstimulation.
Questions This Raises
- ?Could selective mu-opioid blockers in the amygdala reduce overeating?
- ?How do emotional eating patterns relate to amygdala mu-opioid activity?
Trust & Context
- Key Stat:
- Mu-specific feeding Only mu-opioid activation in the amygdala increased food intake
- Evidence Grade:
- Preliminary animal study with clear receptor discrimination but limited to one behavioral measure.
- Study Age:
- Published in 1988 — contributed to understanding of opioid-driven feeding circuits.
- Original Title:
- Involvement of mu opioid receptors in the amygdala in the control of feeding.
- Published In:
- Neuropharmacology, 27(3), 319-26 (1988)
- Authors:
- Gosnell, B A
- Database ID:
- RPEP-00074
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why does the amygdala affect eating?
The amygdala processes emotions and assigns value to experiences including food. Mu-opioid receptors here appear to drive the "wanting" or motivational aspect of eating.
Could this help treat obesity?
Potentially. Blocking amygdala mu-opioid receptors might reduce motivation to eat without affecting pain relief or other opioid functions. However, targeting specific brain regions remains a challenge.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00074APA
Gosnell, B A. (1988). Involvement of mu opioid receptors in the amygdala in the control of feeding.. Neuropharmacology, 27(3), 319-26.
MLA
Gosnell, B A. "Involvement of mu opioid receptors in the amygdala in the control of feeding.." Neuropharmacology, 1988.
RethinkPeptides
RethinkPeptides Research Database. "Involvement of mu opioid receptors in the amygdala in the co..." RPEP-00074. Retrieved from https://rethinkpeptides.com/research/gosnell-1988-involvement-of-mu-opioid
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.